Circulating Osteonectin as a Predictive Biomarker in Patients with Ischemic Symptomatic Chronic Heart Failure

Alexander  Berezin; Alexander A.  Kremzer

doi:10.17795/icrj-9(4)203

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Home

Current Issue All Issues In Press Accepted Manuscripts Search

Instructions

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

https://doi.org/10.17795/icrj-9(4)203

Circulating Osteonectin as a Predictive Biomarker in Patients with Ischemic Symptomatic Chronic Heart Failure

Author(s):

Alexander Berezin^1,*,

Alexander A. Kremzer²

1Department of Internal Medicine, State Medical University, Zaporozhye, Zaporozhye, Ukraine

2Department of Clinical Pharmacology, State Medical University, Zaporozhye, Ukraine

International Cardiovascular Research Journal:Vol. 9, issue 4; e10873

Published online:Dec 31, 2015

Article type:Research Article

Received:May 31, 2014

Accepted:Apr 22, 2015

How to Cite:Alexander BerezinAlexander A. KremzerCirculating Osteonectin as a Predictive Biomarker in Patients with Ischemic Symptomatic Chronic Heart Failure.Int Cardiovasc Res J.9(4):e10873.https://doi.org/10.17795/icrj-9(4)203.

Abstract

Background: Recently, some studies have revealed Osteonectin’s (OSN) promising role as a marker in cardiovascular diseases.
Objectives: This study aimed to evaluate the prognostic value of circulating OSN for cumulative survival and hospitalization in patients with ischemic Chronic Heart Failure (CHF).
Patients and Methods: This open cohort prospective study was conducted on 154 patients with ischemic symptomatic moderate-to-severe CHF at discharge from hospital. The observation period was up to 3 years (156 weeks). Blood samples for biomarker measurements were collected at baseline. ELISA method was used for measurement of OSN circulating level. Then, Receiver Operating Characteristic (ROC) curve analysis was carried out to identify the optimal cut-off points of the OSN concentration with predicted values. Odds ratios were also calculated for all the independent predictors of patients’ survival. Kaplan-Meier survival curves were also structured for both cohorts with low and high OSN levels.
Results: During a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repetitively. The median of circulating OSN levels were 670.96 ng/mL (95% Confidence Interval [CI] = 636.53 - 705.35 ng/mL) and 907.84 ng/mL (95% CI = 878.02 - 937.60 ng/mL) in the survived and dead patients cohorts, respectively. Besides, ROC curve analysis showed that optimal cut-off point of OSN for cumulative survival function was 845.15 ng/mL. The results also revealed significant divergence of Kaplan-Meier survival curves in the patients with high (> 845.15 ng/mL) and low (< 845.15 ng/mL) concentrations of OSN.
Conclusions: Increased circulating OSN levels were associated with increased 3-year CHF-related death, all-cause mortality, and risk of recurrent hospitalization due to CHF.

Keywords

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Alexander Berezin:[PubMed][Scholar]
Alexander A. Kremzer:[PubMed][Scholar]